Mimedx (MDXG) Cash & Equivalents Growth (3y) (2013 - 2026)

Mimedx (MDXG) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Mimedx 635.35 Mn 475.58 Mn 41.62 Mn 37.68%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.68%
Dec 31, 2025 36.06%
Sep 30, 2025 24.73%
Jun 30, 2025 17.92%
Mar 31, 2025 12.04%
Dec 31, 2024 6.24%
Sep 30, 2024 -0.67%
Jun 30, 2024 -6.70%
Mar 31, 2024 -16.98%
Dec 31, 2023 -5.06%
Jun 30, 2023 12.52%
Mar 31, 2023 4.60%
Dec 31, 2022 -1.53%
Sep 30, 2022 -8.02%
Jun 30, 2022 -9.23%
Mar 31, 2022 38.64%
Dec 31, 2021 24.51%
Dec 31, 2020 51.64%
Sep 30, 2020 44.24%
Jun 30, 2020 0.46%